Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Multicenter Study of Iloprost Inhaled in Pulmonary Hypertension After Repair of Congenital Heart Diseases (CHD)

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2016 by Shanghai Jiao Tong University School of Medicine
Cardiothoracic Surgical Group of Chinese Society of Pediatric Surgery
Information provided by (Responsible Party):
Xu Zhuoming, Shanghai Jiao Tong University School of Medicine Identifier:
First received: May 6, 2012
Last updated: April 20, 2016
Last verified: January 2016
This study was designed to investigate treatment of postoperative pulmonary hypertension by iloprost inhalation in children with congenital heart defects. It was a controlled single-blind randomized multi-center prospective study in order to explore the efficacy of this method in the treatment and prevention of pediatric pulmonary hypertension after corrective open-heart surgery for congenital heart defects.

Condition Intervention Phase
Pulmonary Hypertension
Drug: iloprost nebuliser solution
Drug: distilled water
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: Multi-centre, Randomized Study of Iloprost Inhaled in Preventing and Treating Reactive Pulmonary Hypertension (RPH) and Pulmonary Hypertensive Crisis (PHC) After Repair of Congenital Heart Diseases (CHD)

Resource links provided by NLM:

Further study details as provided by Shanghai Jiao Tong University School of Medicine:

Primary Outcome Measures:
  • The total incidence of RPH, PHC or death [ Time Frame: within 48 hours after surgery ] [ Designated as safety issue: No ]

    The primary effective endpoints are reached when any individual components of the primary composite endpoint occur:

    • RPH lasting for more than 30 mintues; or
    • PHC at any time; or
    • death

Secondary Outcome Measures:
  • Change from base line of pulmonary hemodynamic measurements [ Time Frame: within 48 hours after surgery ] [ Designated as safety issue: No ]
    • Pp/Ps
    • NYHA class function
    • SvO2
    • PAO2

Estimated Enrollment: 800
Study Start Date: June 2012
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: iloprost
Iloprost nebuliser solution 500 ng/kg inhaled
Drug: iloprost nebuliser solution
Iloprost nebuliser solution 500 ng/kg inhaled(10 min recommended) q3h for 2 days
Other Name: Ventavis
Placebo Comparator: distilled water
aerosolized distilled water 1-2 ml
Drug: distilled water
1-2 ml aerosolized distilled water inhalation per session
Other Name: Treeful

Detailed Description:

Primary objectives:

  1. To evaluate the effect of iloprost inhaled on postoperative PH after biventricular repair for CHD.
  2. To verify the benefits of iloprost inhaled in improving the hemodynamics after biventricular repair for CHD.

Secondary objectives:

  1. To investigate the preventive effect of iloprost inhaled on the life-threatening PHC occurring immediately after complex congenital heart surgery or occurring just after weaning off cardiopulmonary bypass.
  2. To explore the potential of iloprost inhaled to reduce the early mortality after PHC and to decrease the use of ECMO/VAD.

Ages Eligible for Study:   up to 18 Years   (Child, Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • CHD children who have associated PH risk factors and have accepted biventricular repair
  • Pp/Ps >= 0.75 (before surgery) or Pp/Ps >= 0.5 (after surgery)

Exclusion Criteria:

  • severe mitral stenosis
  • obstructive drainage of pulmonary veins
  • platelet count < 50,000,000,000/L & obvious bleeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01598441

Contact: Zhuomin Xu, PhD 86-21-38626161 ext 6622
Contact: Limin Zhu, MD 86-21-38626161 ext 6622

China, Guangdong
Guangzhou Children's Hospital Recruiting
Guangzhou, Guangdong, China, 510000
Contact: Xinxin Chen         
Principal Investigator: Xinxin Chen, Ph,D         
China, Hubei
Wuhan Asia Hear Hospital Recruiting
Wuhan, Hubei, China, 430022
Contact: Ping Zheng, MD    8627-65796888   
Principal Investigator: Ping Zheng, MD         
Cardiac intensive Care Unit,Department of Thoracic and Cardiovascular Sugery,Shanghai Children's Medical Center Recruiting
Shanghai, China, 200127
Contact: Zhuo-ming Xu, M.D., PhD    8621-38626161 ext 6653   
Contact: Li-min Zhu, M.D.    8621-38626161 ext 6622   
Sub-Investigator: Limin Zhu, MD         
Sponsors and Collaborators
Shanghai Jiao Tong University School of Medicine
Cardiothoracic Surgical Group of Chinese Society of Pediatric Surgery
Principal Investigator: Zhuomin Xu, PhD Shanghai Jiao Tong University School of Medicine
  More Information

Responsible Party: Xu Zhuoming, Director of ICU, Department of thoracic and cardiovascular surgery, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine Identifier: NCT01598441     History of Changes
Other Study ID Numbers: SCMCIRB-201127 
Study First Received: May 6, 2012
Last Updated: April 20, 2016
Health Authority: China: Food and Drug Administration

Keywords provided by Shanghai Jiao Tong University School of Medicine:
pulmonary hypertension, pulmonary hypertensive crisis

Additional relevant MeSH terms:
Hypertension, Pulmonary
Heart Diseases
Heart Defects, Congenital
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Cardiovascular Abnormalities
Congenital Abnormalities
Pharmaceutical Solutions
Platelet Aggregation Inhibitors
Vasodilator Agents processed this record on September 29, 2016